PureTech Health PLC PRTC to Present at Leerink Healthcare Conference (2822D)

TIDMPRTC

RNS Number : 2822D

PureTech Health PLC

18 February 2020

PureTech Health plc

PureTech to Present at 9(th) Annual SVB Leerink Global Healthcare Conference

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") today announced that Daphne Zohar, founder and chief executive officer, will present at the 9(th) Annual SVB Leerink Global Healthcare Conference in New York on Tuesday, 25 February at 9:00 AM EST. A webcast of the presentation will be available at http://puretechhealth.com/investors under the Reports and Presentations tab.

About PureTech Health

PureTech is a clinical stage biotechnology company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune, and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 
 Contact: 
  Investors                  EU media                       US media 
 Allison Mead Talbot       Ben Atwell, Rob Winder         Tom Donovan 
  +1 617 651 3156           +44 (0) 20 3727 1000           +1 857 559 3397 
  amt@puretechhealth.com    ben.atwell@FTIconsulting.com   tom@tenbridgecommunications.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAZZGMZMRDGGZG

(END) Dow Jones Newswires

February 18, 2020 02:00 ET (07:00 GMT)

Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024